Anthera Announces Positive Results from the Extension Period of the SOLUTION Study of Sollpura
Mar 29, 2017 20:12 pm UTC| Business
Sollpura demonstrated comparable maintenance in key measurements of height, weight, and BMISollpura was well tolerated throughout the 20-Week Extension Period HAYWARD, Calif., March 29, 2017 -- Anthera Pharmaceuticals,...
Anthera Announces Positive Results from the Extension Period of the SOLUTION Study of Sollpura
Mar 29, 2017 20:12 pm UTC| Business
Sollpura demonstrated comparable maintenance in key measurements of height, weight, and BMISollpura was well tolerated throughout the 20-Week Extension Period HAYWARD, Calif., March 29, 2017 -- Anthera Pharmaceuticals,...
Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting
Mar 29, 2017 20:12 pm UTC| Business
AUSTIN, Texas, March 29, 2017 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases...
Anthera Announces Positive Results from the Extension Period of the SOLUTION Study of Sollpura
Mar 29, 2017 20:12 pm UTC| Business
Sollpura demonstrated comparable maintenance in key measurements of height, weight, and BMISollpura was well tolerated throughout the 20-Week Extension Period HAYWARD, Calif., March 29, 2017 -- Anthera Pharmaceuticals,...
Anthera Announces Positive Results from the Extension Period of the SOLUTION Study of Sollpura
Mar 29, 2017 20:12 pm UTC| Business
Sollpura demonstrated comparable maintenance in key measurements of height, weight, and BMISollpura was well tolerated throughout the 20-Week Extension Period HAYWARD, Calif., March 29, 2017 -- Anthera Pharmaceuticals,...
Anthera Announces Positive Results from the Extension Period of the SOLUTION Study of Sollpura
Mar 29, 2017 20:12 pm UTC| Business
Sollpura demonstrated comparable maintenance in key measurements of height, weight, and BMISollpura was well tolerated throughout the 20-Week Extension Period HAYWARD, Calif., March 29, 2017 -- Anthera Pharmaceuticals,...
Anthera Announces Positive Results from the Extension Period of the SOLUTION Study of Sollpura
Mar 29, 2017 20:12 pm UTC| Business
Sollpura demonstrated comparable maintenance in key measurements of height, weight, and BMISollpura was well tolerated throughout the 20-Week Extension Period HAYWARD, Calif., March 29, 2017 -- Anthera Pharmaceuticals,...
US–India Trade Talks Race Toward USD 500 Billion Goal